Prognostic significance of 123I-mIBG SPECT myocardial imaging in heart failure: Differences between patients with ischaemic and non-ischaemic heart failure

European Heart Journal Cardiovascular Imaging

Volumn 17, Issue 4, 2016, Pages 384-390

  Clements, Ian P ^a   Kelkar, Anita A ^b   Garcia, Ernest V ^b   Butler, Javed ^c   Chen, Ji ^b   Folks, Russell ^b   Jacobson, Arnold F ^d  

^a MAYO CLINIC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d GE HEALTHCARE   (United States)

Author keywords

heart failure; SPECT myocardial imaging; sympathetic dysinnervation

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; TETROFOSMIN TC 99M; (3 IODOBENZYL)GUANIDINE; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC-99M TETROFOSMIN;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY RISK; MYOCARDIAL PERFUSION IMAGING; NONISCHEMIC CARDIOMYOPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AGED; DIAGNOSTIC IMAGING; HEART MUSCLE ISCHEMIA; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SURVIVAL ANALYSIS;

3-IODOBENZYLGUANIDINE; AGED; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84964282342     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jev295     Document Type: Article

References (34)

1. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981; 22: 129-32.
2. Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging. 2007; 34: 939-50.
3. Travin MI. Cardiac autonomic imaging with SPECT tracers. J Nucl Cardiol. 2013; 20: 128-43; quiz 46.
4. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008; 29: 1147-59.
5. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55: 2212-21.
6. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-Term prognosis in heart failure. JACC Cardiovasc Imaging. 2013; 6: 772-84.
7. Verschure DO, Veltman CE, Manrique A, Somsen GA, Koutelou M, Katsikis A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure?. Results of a pooled individual patient data meta-Analysis. Eur Heart J Cardiovasc Imaging. 2014; 15: 996-1003.
8. Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schaffers M, et al. Proposal for standardization of 123 I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EAMN Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nuc Med Mol Imaging. 2010; 37: 1802-12.
9. Maeno M, Ishida Y, Shimonagata T, Hayashida K, Toyama T, Hirose Y, et al. The significance of 201Tl/123I MIBG (metaiodobenzylguanidine) mismatched myocardial regions for predicting ventricular tachycardia in patients with idiopathic dilated cardiomyopathy. Kaku Igaku. 1993; 30: 1221-9.
10. Marshall A, Cheetham A, George RS, Mason M, Kelion AD. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primary prevention. Heart. 2012; 98: 1359-65.
11. Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellman HN, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation. 1988; 78: 1008-19.
12. Nishimura T, Oka H, Sago M, Matsuo T, Uehara T, Noda H, et al. Serial assessment of denervated but viable myocardium following acute myocardial infarction in dogs using iodine-123 metaiodobenzylguanidine and thallium-201 chloride myocardial single photon emission tomography. Eur J Nucl Med. 1992; 19: 25-9.
13. Zipes DP. Influence of myocardial ischemia and infarction on autonomic innervation of heart. Circulation. 1990; 82: 1095-105.
14. Mitrani RD, Klein LS, Miles WM, Hackett FK, BurtRW, Wellman HN, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol. 1993; 22: 1344-53.
15. Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003; 10: 121-31.
16. Bax JJ, Kraft O, Buxton AE, Fjeld JG, Parizek P, Agostini D, et al. 123 I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008 1 131-40.
17. Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010; 55: 2769-77.
18. Clements IP GE, Chen J, Folks R, Butler J, Jacobson AF. Quantitative iodine 123 meta-iodobenzylguanidine (123I mIBG) SPECT imaging in heart failure with left ventricular systolic dysfunction development and validation of automated procedures in conjunction with technetium-99 m tetrofosmin myocardial perfusion SPECT. J Nucl Cardiol. 2015; In Press
19. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol. 2009 16g 113-21.
20. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, LaskeyWK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002; 105: 539-42.
21. Ketchum ES, Jacobson AF, Caldwell JH, Senior R, Cerqueira MD, Thomas GS, et al. Selective improvement in Seattle heart failure model risk stratification using Iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol. 2012; 19: 1007-16.
22. Sood N, Al Badarin F, Parker M, Pullatt R, Jacobson AF, Bateman TM, et al. Resting perfusion MPI-SPECT combined with cardiac 123I-mIBG sympathetic innervation imaging improves prediction of arrhythmic events in non-ischemic cardiomyopathy patients: sub-study from the ADMIRE-HF trial. J Nucl Cardiol. 2013; 20: 813-20.
23. Shaw LJ, Hendel R, Borges-Neto S, Lauer MS, Alazraki N, Burnette J, et al. Prognostic value of normal exercise and adenosine (99 m)Tc-Tetrofosmin SPECT imaging: results from the multicenter registry of 4, 728 patients. J Nucl Med. 2003; 44: 134-9.
24. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994; 89: 151-63.
25. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, et al. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol. 1995; 27: 291-305.
26. Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi AA, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-Term mortality. Circulation. 2012; 126: 1206-16.
27. Wong TC, Piehler K, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014; 35: 657-64.
28. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992; 85: 790-804.
29. Albino Teixeira A, Azevedo I, Branco D, Rodrigues-Pereira E, Osswald W. Sympathetic denervation caused by long-Term noradrenaline infusions; prevention by desipramine and superoxide dismutase. Br J Pharmacol. 1989; 97: 95-102.
30. Merlet P, Hittinger L, Dubois-Rande JL, Castaigne A. Myocardial adrenergic dysinnervation in dilated cardiomyopathy: cornerstone or epiphenomenon?. J Nucl Med. 2002; 43: 536-9.
31. Garcia EV, Faber TL, Cooke CD, Folks RD, Chen J, Santana C. The increasing role of quantification in clinical nuclear cardiology: the Emory approach. J Nucl Cardiol. 2007; 14: 420-32.
32. Chen J, Garcia EV, Galt JR, Folks RD, Carrio I. Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol. 2006; 13: 251-60.
33. Shaw LJ, Hendel RC, Cerquiera M, Mieres JH, Alazraki N, Krawczynska E, et al. Ethnic differences in the prognostic value of stress technetium-99 m tetrofosmin gated single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol. 2005; 45: 1494-504.
34. Berman DS, Hachamovitch R, Kiat H, Cohen I, Cabico JA, Wang FP, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99 m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol. 1995; 26: 639-47.